-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned...
Barchart Research What to Expect from XNCR Earnings XNCR Generated August 4, 2026 Current Price $19.92 EPS Estimate $$-0.82 Consensus Rating Strong Buy Average Move 4.82% Xencor's Pipeline Momentum Meets...
-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex-U.S. royalties remain unchanged --
-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027...
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...
-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study...
-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.77%. June E-mini...